therapeutic efficacy of hydrochlorothiazide in primary monosymptomatic nocturnal enuresis in boys with idiopathic hypercalciuria

patients and methods this study was a randomized double-blind placebo-controlled clinical trial. a hundred boys with pmne and ihc were randomly assigned into two groups of experimental (treated with hct 1 mg/kg/day) and control and all patients were followed for 4 months for the number of wet-night episodes. results the mean numbers of wet-night episodes in the first (intervention: 8.34 ± 8.54, control: 9.1 ± 9.3, p = 0.3), second (7.1 ± 7.3, 7.9 ± 8.1, p = 0.4), third (7.8 ± 8, 7.9 ± 8.1, p = 0.1) and fourth (4.9 ± 5.1, 5.9 ± 6, p = 0.3) months were not significantly different between the two groups. however, the decrease in the average wet-night episodes during the 4 months of treatment in the intervention group (p = 0.019) unlike the control group. not more significant compared to control group (p = 0.191). all patients who were treated by hct became normocalciuric. however, in 21 patients the dose was increased to 2 mg/kg/day. conclusions single daily dose of hct is a safe and effective therapeutic option in the treatment of pmne in children with ihc. objectives the aim of this study was to assess the therapeutic efficacy of hct in boys with primary monosymptomatic ne (pmne). background idiopathic hypercalciuria (ihc) can be one of the causes of nocturnal enuresis (ne) and hydrochlorothiazide (hct) ameliorates hypercalciuria.